Casdin Capital 13F holdings, Q3 2016
Holdings as of September 30, 2016 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 26 US equity positions worth $123.5m in its Q3 2016 13F filing. The largest position was AGIO at 12.1% of the reported book, followed by SG7 and FOUNDATION MEDICINE INC. Against the Q2 2016 filing, it opened 6 new positions, added to 7 and reduced 12 among the top 26 holdings.
What did Casdin Capital own in Q3 2016? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2016 |
|---|---|---|---|---|---|---|---|
| 1 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 12.1% | $14.9m | 282,443 | 51% | added |
| 2 | SG7 SAGE THERAPEUTICS INC | 9.9% | $12.3m | 266,500 | 17% | added | |
| 3 | FOUNDATION MEDICINE INC | 7.8% | $9.7m | 415,000 | 6% | added | |
| 4 | EVH EVOLENT HEALTH INC | Healthcare | 7.7% | $9.5m | 385,000 | 61% | added |
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 6.9% | $8.5m | 287,000 | -16% | reduced | |
| 6 | LOXO ONCOLOGY INC | 6.2% | $7.6m | 291,000 | -3% | reduced | |
| 7 | GNMK GENMARK DIAGNOSTICS INC | 6.0% | $7.4m | 625,000 | 51% | added | |
| 8 | SPARK THERAPEUTICS INC | 4.5% | $5.6m | 93,500 | -42% | reduced | |
| 9 | GLOBAL BLOOD THERAPEUTICS IN | 4.5% | $5.5m | 240,000 | -44% | reduced | |
| 10 | KITE PHARMA INC | 4.1% | $5.0m | 90,000 | 24% | added | |
| 11 | BLUEBIRD BIO INC | 3.3% | $4.1m | 60,000 | -51% | reduced | |
| 12 | CLOVIS ONCOLOGY INC | 3.2% | $4.0m | 110,000 | -27% | reduced | |
| 13 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.7% | $3.3m | 276,500 | -14% | reduced |
| 14 | EPIZYME INC | 2.4% | $2.9m | 295,000 | -13% | reduced | |
| 15 | EXK EXACT SCIENCES CORP | Basic Materials | 2.3% | $2.9m | 155,000 | – | new |
| 16 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.1% | $2.6m | 39,000 | -46% | reduced |
| 17 | MDRX ALLSCRIPTS HEALTHCARE SOLUTN | Healthcare | 2.1% | $2.6m | 200,000 | – | new |
| 18 | MYOKARDIA INC | 2.1% | $2.6m | 160,000 | -11% | reduced | |
| 19 | GHDX GENOMIC HEALTH INC | 2.1% | $2.6m | 90,000 | – | new | |
| 20 | MEDGENICS INC | 1.7% | $2.1m | 375,000 | 341% | added | |
| 21 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.6% | $2.0m | 127,500 | -46% | reduced |
| 22 | IBB ISHARES TR | 1.2% | $1.4m | 5,000 | – | new | |
| 23 | IGNYTA INC | 1.0% | $1.2m | 195,000 | -48% | reduced | |
| 24 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 1.0% | $1.2m | 33,000 | – | new |
| 25 | EDIT EDITAS MEDICINE INC | Healthcare | 0.9% | $1.2m | 85,470 | – | new |
| 26 | SYROS PHARMACEUTICALS INC | 0.6% | $694.0k | 50,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.